Events Calendar
January 9-12, 2023
41st Annual JP Morgan Health Care Conference
San Francisco, CA
Stephen Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer; Mr. Scott Beck, MBA, Vyriad Chief Operating Officer; Kah-Whye Peng, Ph.D., Vyriad Chief Technical Officer; and Luke Russell, Ph.D., Vyriad Director of Business Development and Strategic Alliances will be attending the 41st Annual JP Morgan Health Care Conference.
December 7-9, 2022
ESMO Immuno-Oncology Congress
Geneva, Switzerland
Kah-Whye Peng, Ph.D., Vyriad Chief Technical Officer will be attending the 2022 ESMO Immuno-Oncology Congress
December 10-13, 2022
American Society of Hematology Annual Meeting
Virtual
Stephen Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer will be attending the ASH Annual Meeting virtually.
December 6-8, 2022
7th Oncolytic Virotherapy Summit
Boston, MA
Stephen Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer. Presentation: “Intravenous Administration of an Oncolytic Vesicular Stomatitis Virus: Clinical Experience to Date.”
Sheryl Tran, Vyriad Senior Director, Quality and Compliance. Presentation: Workshop A – Advancing CMC, Quality Control & Manufacturing Policies
October 23-26, 2022
14th International Oncolytic Virotherapy Conference
Nagano, Japan
Kah-Whye Peng, Ph.D., Vyriad Chief Technical Officer will be attending the 14th International Oncolytic Virotherapy Conference
June 13-16, 2022
BIO International Convention
San Diego, CA
Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer, Kah-Whye Peng, Ph.D., Vyriad Chief Technical Officer, and Luke Russell, Ph.D., Vyriad Director of Alliance Management will be attending the BIO International Convention in San Diego.
June 3-7, 2022
American Society of Clinical Oncology Annual Meeting (ASCO)
Chicago, IL
Luke Russell, Ph.D., Vyriad Director of Alliance Management and Alice Bexon, M.D., Vyriad Chief Medical Officer. Poster Presentation: Jose Lutzky, M.D., University of Miami Health System. VV1 oncolytic virus + cemiplimab + Ipilimumab in patients with melanoma or NSCLC
May 15-19, 2022
American Society of Gene & Cell Therapy 25th Annual Meeting (ASGCT)
Washington, DC
Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer, attending the ASGCT Annual Meeting virtually.
January 10-13, 2022
40th Annual JP Morgan Health Care Conference
Virtual
Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer, Kah-Whye Peng, Ph.D., Vyriad Chief Technical Officer, and Luke Russell, Ph.D., Vyriad Director of Alliance Management attended the virtual 40th Annual JP Morgan Health Care Conference
November 10-14, 2021
The Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting & Pre-Conference Programs (SITC)
Washington, DC
Dr. Alice Bexon, Vyriad, Chief Medical Officer; Vino Raj, Vyriad, Medical Director; and Rebecca Thomason, Vyriad, Clinical Program Manager, will be attending the 36th SITC meeting in Washington, DC
November 5-7, 2021
International Oncolytic Virus Conference (IOVC)
Sedona, AZ / virtual meeting
Dr. Kah Whye Peng was presented with the Golden Virus Award for her outstanding contribution to the field of virotherapy.
October 7-10, 2021
AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer
Virtual Meeting
Dr. Shruthi Naik, Vyriad, Vice President, Comparative Oncology. Poster presentation: Safety and efficacy of neoadjuvant intravesical MV-NIS in patients with urothelial carcinoma
October 5-6, 2021
Cambridge Health Institute’s (CHI) 6th Annual Oncolytic Virus Immunotherapy Summit
Virtual
Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer. Presentation: “Resurgence of the Oncolytic Measles Platform: Armed, Resurfaced and Precision Targeted.”
September 9-10, 2021
The 27th Annual Meeting of the Japan Society of Gene and Cell Therapy (JSGCT)
Tokyo, Japan
Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer. Presentation: “Intravenous Oncolytic Virotherapy Using Voyager-V1 (VSV-IFNb-NIS).”
June 8-10, 2021
2021 Antibody Engineering and Therapeutics Europe Meeting
Virtual
Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer. Presentation: “Lentiviral Vectors Stealthed for In Vivo T Cell Transduction and Retargeted Via Surface Display of a CD3-Specific scFv.”
June 1, 2021
Medlab Middle East – Genetics Focus Day, Dubai
Virtual
Dr. Rianna Vandergaast, Principal Scientist for Imanis Life Sciences. Presentation: “IMMUNO-COV: Measuring Protection From SARS-CoV-2.”
May 19-21, 2021
7th Annual World Medical Innovation Forum
Virtual
Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer. Presentation: “Entrepreneurial Growth / Oncolytic Virus.” Panel Discussion: “Entrepreneurial Snapshot / Growing Capability Company by Company”
May 11-14, 2021
American Society of Gene & Cell Therapy 24th Annual Meeting (ASGCT) Virtual
Stephen J. Russell, M.D., Ph.D., President of ASGCT and Vyriad Chief Executive Officer presented the “Welcome Statement”.
Dr. Russell held the “Fireside Chat” with Jennifer A. Doudna, Ph.D., co-recipient of the 2020 Nobel Prize in Chemistry for the discovery of the genome-editing tool CRISPR-Cas9.
Dr. Russell chaired the following Roundtable Discussion:
“COVID-19: Vaccines to the Rescue” with Sarah Gilbert, Ph.D., University of Oxford; Larry Corey, M.D., Fred Hutchinson Cancer Research Center; Gregory Poland, M.D., Mayo Clinic; Ligia Pinto, Ph.D., Frederick National Laboratory for Cancer Research and Philip Dormitzer, M.D., Ph.D., Pfizer
October 26, 2020
Career Path Workshop at Sanford Research
Sioux Falls, SD
Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer Kah-Whye Peng, Ph.D., Vyriad Chief Technical Officer. Presentation: “Career Paths in Industry.”
October 6-8, 2020
Cambridge Health Institute’s (CHI) 5th Annual Oncolytic Virus Immunotherapy Summit
Virtual
Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer. Presentation: “Engineering the Immune Response to Blaze a Trail for Oncolytic Immunotherapy.” Panel Discussion: Current Challenges in Oncolytic Virotherapy
May 29-June 2 2020
American Society of Clinical Oncology
Virtual
Poster Presentations:
Ph 2 trial of Voyager-V1 (vesicular stomatitis virus expressing human IFNβ and NIS, VV1), in combination with cemiplimab (C) in patients with NSCLC, melanoma, HCC or endometrial carcinoma
Relationship of infusion duration to safety, efficacy, and pharmacodynamics (PD): Second part of a phase I-II study using VSV-IFNβ-NIS (VV1) oncolytic virus in patients with refractory solid tumors
Safety and efficacy of neoadjuvant intravesical oncolytic MV-NIS in patients undergoing radical cystectomy (RC) for urothelial carcinoma but ineligible for neoadjuvant cisplatin-based chemotherapy
May 12-15, 2020
American Society of Gene & Cell Therapy 23rd Annual Meeting (ASGCT)
Virtual
Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer. Presentation: Education Talk with Overview “Choosing the OV Platform: Considerations”
December 3-5, 2019
Oncolytic Virotherapy Summit
Boston, MA
Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Presentation: “Pharmico-Dynamic Non-Invasive Monitoring Techniques”
See Speakers
October 28-31, 2019
World Vaccine Congress Europe 2019
Barcelona, Spain
Shruthi Naik, Ph.D., Vyriad Vice President of Comparative Oncology
Presentation: “Unlocking the Potential of Oncolytic Viruses to Target Cancer Cells”
October 9-12, 2019
International Oncolytic Virus 12th Annual Conference
Rochester, MN
Kah-Whye Peng, Ph.D., Vyriad Chief Technical Officer
Opening Remarks
Stephen Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Presentation: “Inflaming tumors with systemic VSV therapy”
August 8, 2019
Cambridge Healthtech Institutes (CHI) 2nd Annual Immuno-Oncology Investing & Partnering Forum
Boston, MA
Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Presentation: “Novel Therapeutics and Diagnostics for Cancer Immunotherapy”
August 6-7, 2019
Cambridge Health Institute’s (CHI) 4th Annual Oncolytic Virus Immunotherapy Summit
Boston, MA
Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Presentation: “Systemic OV Therapy Using Voyager-V1”
July 21-23, 2019
The 25th Annual Meeting of Japan Society of Gene and Cell Therapy and The International Gene & Cell Therapy Symposium
Tokyo, Japan
Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Presentation: “Intravenous Virotherapy: Inflaming Tumors via the Blood Stream”
April 10-11, 2019
Cambridge Healthtech Institute’s Inaugural Oncolytic Viral Therapy Conference: Engineering, Translational and Clinical Strategies
Boston, MA
Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Presentation: “Antibody Targeted Viruses: The Next Generation of Oncolytics”
March 18-22, 2019
Immuno-Oncology Summit Europe
London, UK
Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Presentation: “Vyriad’s Voyager-V1 Program: Pharmacological Enhancement of a Systemically Active, Single Cycle Oncolytic Virus”
March 11-13, 2019
Cambridge Healthtech Institute’s 4th Annual Cancer Immunotherapy: Executive Summit
San Francisco, CA
Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Presentation: “Voyager-V1: Systemic, Single-cycle, Trackable Oncolytic Virotherapy”
February 11-12, 2019
Bio CEO and Investor Conference
New York, NY
Kah-Whye Peng, Ph.D., Vyriad Chief Technical Officer
Presentation: “Oncolytic Viruses for IV Cancer Therapy”
January 7-10, 2019
37th Annual JP Morgan Healthcare Conference
San Francisco, CA
Stephen J. Russell, M.D., Ph.D., Vyriad CEO, and Kah-Whye Peng, Ph.D., Vyriad Chief Technical Officer, attended the 37th Annual JP Morgan Healthcare Conference in San Francisco.
December 4-6, 2018
4th Oncolytic Virotherapy Summit
Boston, MA
Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Presentation: “Vyriad’s Voyager-V1 Program: Pharmacological Enhancement of a Systemically Active, Single Cycle Oncolytic Virus.”
Dr. Russell will also co-chair a panel session entitled: Comparing and Contrasting Virus Types.
November 27-29, 2018
30th Annual Piper Jaffray Healthcare Conference
New York, NY
Stephen J. Russell, M.D., Ph.D., Vyriad President and CEO, attended the 30th Annual Piper Jaffray Healthcare Conference in New York.
August 27-28, 2018
Cambridge Healthtech Institute’s 3rd Annual Oncolytic Virus Immunotherapy: Commercializing the Exciting Potential of Oncolytic Virotherapy
Boston, MA
Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Presentation: “Progress with Oncolytic Vesicular Stomatitis Viruses”
June 26-28, 2018
Armed Oncolytic Immunotherapies Summit
Frankfurt, Germany
Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Presentation: “Systemic Cancer Therapy Using Oncolytic VSVs: The Voyager Platform”
Dr. Russell will participate in a panel discussion, “Explore Novel Approaches to Identify the Most Rational Combinations“
June 1-5, 2018
American Society of Clinical Oncology (ASCO) Annual Meeting
Chicago, Illinois
Alice Bexon, M.D., Vyriad Chief Medical Officer will attend the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.
May 16-19, 2018
18th Annual American Society of Cell & Gene Therapy (ASGCT) meeting
Chicago, IL
Stephen J. Russell, M.D., Ph.D., Vyriad CEO, has been elected Vice-President of ASGCT. ASGCT has elected four new members to the Board of Directors, including Dr. Stephen J. Russell as new incoming vice president. Dr. Russell will serve a yearlong term as vice president before serving as ASGCT’s president-elect and, finally, president through the 2021 annual meeting. Dr. Russell will be Co-Chairing: Clinical Trials Spotlight I at the annual meeting. Kah-Whye Peng, Ph.D., Vyriad Chief Technology Officer, has been invited to present: Use of Novel Transgenic NIS Reporter Rats for Longitudinal Tracking of Fibrogenesis by High-Resolution Imaging and Use of Novel Transgenic NIS Reporter Rats for Longitudinal Tracking of Fibrogenesis by High-Resolution Imaging
April 9-12, 2018
International Oncolytic Virus Conference
Oxford, UK
Stephen J. Russell, M.D., Ph.D., Vyriad CEO, has been invited to Chair, Innate and collateral adaptive tumor immunity. Dr. Russell will also participate in Steve Russell (Once should be enough!) vs. Alan Melcher (Repeat dosing is crucial!) Kah-Whye Peng, Ph.D., Vyriad Chief Technology Officer, has been invited to Chair, Translation, imaging and clinical breakthroughs. Dr. Peng will be presenting: Oncolytic virus encoding IFNbeta: optimizing therapeutic index.
January 8-11, 2018
36th Annual JP Morgan Healthcare Conference
San Francisco, CA
Stephen J. Russell, M.D., Ph.D., Vyriad CEO, and Kah-Whye Peng, Ph.D., Vyriad Chief Technical Officer, attended the 36th Annual JP Morgan Healthcare Conference in San Francisco.
December 5-7, 2017
Oncolytic Virotherapy Summit
Miami, Florida
Stephen J. Russell, M.D., Ph.D., Vyriad CEO, was invited as a panel member for: How Can We Improve the Efficacy of Oncolytic Virotherapies? Dr. Russell also provided a presentation entitled “VSV-IFNb-NIS and MV-NIS: A Tale of Two Paradigms” and managed a workshop entitled “Optimizing Oncolytic Viruses: Identifying the Right Viral Platform”
November 28-29, 2017
29th Annual Piper Jaffray Healthcare Conference
New York, New York
Stephen J. Russell, M.D., Ph.D., Vyriad CEO, presented “Oncolytic Virotherapy: The Next Major Breakthrough in Cancer Treatment” at the 28th Annual Piper Jaffray Healthcare Conference
November 8-12, 2017
The 32nd Annual Society for Immunotherapy of Cancer (SITC) meeting
National Harbor, Maryland
Stephen J. Russell, M.D., Ph.D., Vyriad CEO, attended the annual SITC meeting
November 4, 2017
Dr. Boenjamin Setiawan Distinguished Lectureship for 2017
Jakarta, Indonesia
Stephen Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Invited to present “Oncolytic Viruses: An Emerging Cornerstone for Immuno-oncology” at the Dr. Boenjamin Setiawan Distinguished Lecture Series
February 23-25, 2017
ASCO-SITC Clinical Immuno-Oncology Symposium
Orlando, Florida
Stephen J Russell from Vyriad was invited to present on “Viral Therapy” at the ASCO-SITC conference on exploiting viruses for cancer therapy in combination with immune modulators.
October 1-4, 2016
The 10th International Meeting on Replicating Oncolytic Virus Therapeutics
Vancouver, Canada
Kah-Whye Peng, PhD, CTO of Vyriad gave a Plenary presentation entitled “Vesicular stomatitis virus (VSV) as an oncolytic agent”. Stephen J. Russell, MD, PhD, CEO & President of Vyriad gave a Plenary presentation entitled “Measles as a versatile oncolytic agent”.
June 18, 2016
35th Annual Meeting of the American Society of Virology
Blacksburg, VA
Keynote Lecture: “Oncolytic Viruses: Past, Present, and Future” Stephen J. Russell, MD, PhD, CEO & President, Vyriad.